Brazil’s national sanitary regulator Anvisa authorized the use of Pfizer’s Comirnaty vaccine for children aged 12 years old and older. The jab’s leaflet will now also include this age group.
The expansion was approved, Anvisa stated, after studies were unveiled by laboratories indicating the safety and efficiency of the vaccine for this group. The research was carried out overseas and assessed by the Brazilian watchdog.
Comirnaty is the only vaccine authorized in Brazil for people younger than 18. It was the first to receive definitive registration status as a vaccine against COVID-19 in the country.